Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer

Squamous-cell carcinoma represents approximately 30% of all cases of non-small-cell lung cancer (NSCLC).1 Treatment for advanced squamous-cell NSCLC remains an unmet need; little therapeutic progress has been made since the approval of docetaxel for second-line treatment in 1999.2-4 Most new agents...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Brahmer, Julie (VerfasserIn) , Steins, Martin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 9 July 2015
In: The New England journal of medicine
Year: 2015, Jahrgang: 373, Heft: 2, Pages: 123-135
ISSN:1533-4406
DOI:10.1056/NEJMoa1504627
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1504627
Volltext
Verfasserangaben:Julie Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried E.E. Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina C. Garassino, Joachim G. Aerts, Manuel Domine, Luis Paz-Ares, Martin Reck, Christine Baudelet, Christopher T. Harbison, Brian Lestini, David R. Spigel

MARC

LEADER 00000caa a2200000 c 4500
001 1555760031
003 DE-627
005 20230426153642.0
007 cr uuu---uuuuu
008 170322s2015 xx |||||o 00| ||eng c
024 7 |a 10.1056/NEJMoa1504627  |2 doi 
035 |a (DE-627)1555760031 
035 |a (DE-576)485760037 
035 |a (DE-599)BSZ485760037 
035 |a (OCoLC)1340962967 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Brahmer, Julie  |e VerfasserIn  |0 (DE-588)1126199958  |0 (DE-627)880808160  |0 (DE-576)483761664  |4 aut 
245 1 0 |a Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer  |c Julie Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried E.E. Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina C. Garassino, Joachim G. Aerts, Manuel Domine, Luis Paz-Ares, Martin Reck, Christine Baudelet, Christopher T. Harbison, Brian Lestini, David R. Spigel 
264 1 |c 9 July 2015 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 22.03.2017 
520 |a Squamous-cell carcinoma represents approximately 30% of all cases of non-small-cell lung cancer (NSCLC).1 Treatment for advanced squamous-cell NSCLC remains an unmet need; little therapeutic progress has been made since the approval of docetaxel for second-line treatment in 1999.2-4 Most new agents for the treatment of NSCLC are not indicated for this subtype because of their toxicity or lack of efficacy or because their activity is limited to tumors with specific genetic alterations that are rarely found in squamous-cell NSCLC.5-7 Furthermore, no single-agent therapy has resulted in better survival than that seen with docetaxel. The programmed death 1 (PD-1) . . . 
700 1 |a Steins, Martin  |d 1971-  |e VerfasserIn  |0 (DE-588)121323900  |0 (DE-627)705384837  |0 (DE-576)292647379  |4 aut 
773 0 8 |i Enthalten in  |t The New England journal of medicine  |d Waltham, Mass. : MMS, 1928  |g 373(2015), 2, Seite 123-135  |h Online-Ressource  |w (DE-627)266889484  |w (DE-600)1468837-2  |w (DE-576)075962454  |x 1533-4406  |7 nnas  |a Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer 
773 1 8 |g volume:373  |g year:2015  |g number:2  |g pages:123-135  |g extent:13  |a Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer 
856 4 0 |u http://dx.doi.org/10.1056/NEJMoa1504627  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://dx.doi.org/10.1056/NEJMoa1504627  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20170322 
993 |a Article 
994 |a 2015 
998 |g 121323900  |a Steins, Martin  |m 121323900:Steins, Martin  |d 910000  |d 950000  |d 950900  |e 910000PS121323900  |e 950000PS121323900  |e 950900PS121323900  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 16 
999 |a KXP-PPN1555760031  |e 2960908155 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"title_sort":"Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer","title":"Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer"}],"person":[{"display":"Brahmer, Julie","roleDisplay":"VerfasserIn","role":"aut","family":"Brahmer","given":"Julie"},{"given":"Martin","family":"Steins","role":"aut","display":"Steins, Martin","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 22.03.2017"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1555760031","language":["eng"],"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"9 July 2015"}],"id":{"eki":["1555760031"],"doi":["10.1056/NEJMoa1504627"]},"name":{"displayForm":["Julie Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried E.E. Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina C. Garassino, Joachim G. Aerts, Manuel Domine, Luis Paz-Ares, Martin Reck, Christine Baudelet, Christopher T. Harbison, Brian Lestini, David R. Spigel"]},"physDesc":[{"extent":"13 S."}],"relHost":[{"pubHistory":["198.1928 -"],"titleAlt":[{"title":"NEJM"}],"part":{"volume":"373","text":"373(2015), 2, Seite 123-135","extent":"13","year":"2015","pages":"123-135","issue":"2"},"disp":"Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancerThe New England journal of medicine","note":["Gesehen am 04.08.25"],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"Massachusetts Medical Society"}],"language":["eng"],"recId":"266889484","title":[{"title_sort":"New England journal of medicine","subtitle":"NEJM","title":"The New England journal of medicine"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Waltham, Mass. ; Boston, Mass.","dateIssuedKey":"1928","publisher":"MMS ; MMS","dateIssuedDisp":"1928-"}],"id":{"issn":["1533-4406"],"eki":["266889484"],"zdb":["1468837-2"]},"name":{"displayForm":["Massachusetts Medical Society"]}}]} 
SRT |a BRAHMERJULNIVOLUMABV9201